Research
Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide 15 mg) produce significant weight loss (15–21%) and improve obesity-related comorbidities, but discontinuation leads to substantial weight regain, necessitating long-term maintenance therapy.
Use FDA-approved GLP-1 or dual agonists for significant obesity. These drugs work by mimicking gut hormones to reduce appetite and increase satiety. You must take them long-term; stopping leads to weight regain. Discuss titration schedules with your doctor to manage side effects like nausea.
StrongQualifiesVERY_HIGH confidence
Recent pharmacological advancements have substantially transformed obesity management. Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (2.4 mg) and the dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide (15 mg) have demonstrated significant weight loss effects (15–21%)... Despite encouraging outcomes, significant challenges remain. Issues such as weight regain after discontinuation... continue to present obstacles.
Why this rating
Based on multiple large-scale Phase 3 RCTs (STEP, SURMOUNT) cited in the review.
Source
Recent advances in the pharmacological treatment of obesity
Ga Eun Nam · Journal of Korean Medical Association · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →